Drug Trial Radar · NCT04549168
A Study of Lemborexant in Chinese Participants With Insomnia Disorder
Last checked: Nov 20, 2026Latest source record: Dec 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
194
Actual
Start
Nov 6, 2020
Primary completion
Mar 17, 2023
Study completion Mar 17, 2023
Sponsor
- Lead sponsor
- Eisai Co., Ltd.Eisai
- Sponsor type
- Industry
- First posted
- Sep 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to confirm using polysomnography (PSG) that lemborexant 10 milligram (mg) is superior to placebo on objective sleep onset as assessed by latency to persistent sleep (LPS) during the last 2 nights of 1 month of treatment in participants with insomnia disorder.
Conditions
- Sleep Initiation and Maintenance Disorders
Interventions
LemborexantDrug
Lemborexant 10 mg tablet.
PlaceboDrug
Placebo tablet matched to lemborexant 10 mg tablet.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline of Mean Latency to Persistent Sleep (LPS) Over the Last 2 Nights of 1 Month of Treatment of Lemborexant 10 mg Compared to PlaceboTime frame: Baseline, Days 29 and 30
Locations
23 sites in 2 countries. Site status is shown where the registry gives one.
Beijing Tiantan Hosptial, Capital Medical University
Beijing, Beijing Municipality, China
Peking University Sixth Hospital
Beijing, Beijing Municipality, China
Xuanwu Hospital Capital Medical University
Beijing, Beijing Municipality, China
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China
The First Affiliated Hospital of Jinan University
Guangzhou, Guangdong, China
The First Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
The Third Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Henan Mental Health Center
Xinxiang, Henan, China
Wuhan Mental Health Center
Wuhan, Hubei, China
Nanjing Brain Hosptial
Nanjing, Jiangsu, China
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Jilin First University Affiliated Hospital
Changchun, Jilin, China
Inner Mongolia Autonomous Region Peoples Hospital
Hohhot, Mongolia, China
Tangdu Hospital
Xi'an, Shaanxi, China
Shandong Provincial Qianfushan Hospital
Jinan, Shandong, China
Huashan Hospital Fudan University
Shanghai, Shanghai Municipality, China
Shanghai Mental Health Center
Shanghai, Shanghai Municipality, China
First Hospital of Shanxi Medical University
Taiyuan, Shannxi, China
Tianjin Anding Hospital
Tianjin, Tianjin Municipality, China
Taipei Veterans General Hospital
Taipei, Taiwan
Chang Gung Medical Foundation Linkou Chang Gung Memorial Hospital
Taoyuan, Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.